Invests in
Min Investment:
$100,000.00Max Investment:
$5,000,000.00Target Investment:
$1,500,000.00
Education
Postdoc
Research Institute of Molecular Pathology(1992 - 1994)
Lists including Christoph
Work Experience
2022
CSO & co-founder
2022
Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling dataset that enables an awesome Series A financing. And we do this at scale for 40+ companies / year.
Adjunct Associate Professor
2005
Principal Investigator
1994 - 2005
Co-lead the molecular genetics lab together with Bert Vogelstein and Ken Kinzler. Was involved in the identification of several cancer driver genes incl. BRAF and PIK3CA. Discovered that all cancers are genetically unstable which explains the molecular heterogeneity of cancer and why cancers develop resistance to cancer drugs.
2019 - 2022
Consultant, R&D strategy
2021 - 2022
We envision a future where routine preventative care includes a blood test for cancer, just as patients are now routinely tested for early stages of heart disease. We know that if cancer is caught early, it often can be cured.
Chief Innovation Officer & co-founder
2019 - 2021
2017 - 2022
CEO & founder
2017 - 2022
Advise Connect Inspire (ACI) helps European life sciences startups and emerging companies. We provide tailored support for young companies ranging from high-level strategic guidance to operational and tactical assistance. We are convinced that the complexity of building and growing a life sciences company calls for programs that are flexible and built around the needs of each company. We also understand the unique challenges of European companies that are trying to navigate a new ecosystem, and we know how to best help them.
2016 - 2022
Partner
2018 - 2022
Third Rock’s strategy is to discover, launch and build great companies - based on bold ideas that meet at the intersection of science, strategy, business and medicine. Blueprint - Relay - Celsius - Thrive - MOMA
Venture Partner
2016 - 2018
2012 - 2021
Executive Vice President
2016 - 2021
Integrated Drug Development. Blueprint's singular focus is to use our deep understanding of the genetic blueprint of cancer and rare genetic diseases driven by the abnormal activation of kinases to craft highly selective medicines aimed at eradicating these diseases.
CSO
2012 - 2016
Chief Drug Hunter AYVAKIT (avapritinib) is a KIT/PDGFRA inhibitor approved for patients with advanced systemic mastocytosis (SM) and for patients with gastrointestinal stromal tumor (GIST), GAVRETO (pralsetinib) is a RET inhibitor approved for patients with RET+ non-small-cell lung carcinoma (NSCLC) and RET+ thyroid cancer.
2020 - 2021
CSO & co-founder
2020 - 2021
Molecular machines are enzymes that create force, work, and motion. We will discover the next generation of precision medicines by targeting the molecular machines that underlie human disease.
2018 - 2020
CSO, president & co-founder
2018 - 2020
How cells work together defines who we are, how we function and the diseases we have. Now, for the first time, we are able to see how individual cells interact at a level of resolution that was not previously possible.
2018 - 2019
Associate
2018 - 2019
The Creative Destruction Lab is a seed-stage program for massively scalable, science-based companies.
2015 - 2019
CEO
2015 - 2019